Harvard Bioscience Inc. (NASDAQ:HBIO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.
According to Zacks, “HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. “
Harvard Bioscience (NASDAQ:HBIO) opened at 2.85 on Friday. Harvard Bioscience has a 12 month low of $2.41 and a 12 month high of $4.24. The company has a 50-day moving average of $2.67 and a 200-day moving average of $2.97. The company’s market cap is $97.79 million.
Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.03. Harvard Bioscience had a positive return on equity of 3.40% and a negative net margin of 18.04%. The business earned $26.10 million during the quarter, compared to analyst estimates of $26.60 million. Analysts predict that Harvard Bioscience will post $0.16 EPS for the current year.
Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC increased its position in Harvard Bioscience by 2.2% in the first quarter. Acadian Asset Management LLC now owns 707,818 shares of the company’s stock worth $2,138,000 after buying an additional 15,028 shares during the period. Heartland Advisors Inc. increased its position in Harvard Bioscience by 7.1% in the second quarter. Heartland Advisors Inc. now owns 2,200,000 shares of the company’s stock worth $6,292,000 after buying an additional 145,778 shares during the period. Royce & Associates LP increased its position in Harvard Bioscience by 17.0% in the first quarter. Royce & Associates LP now owns 1,546,000 shares of the company’s stock worth $4,669,000 after buying an additional 225,000 shares during the period. Teton Advisors Inc. increased its position in Harvard Bioscience by 0.6% in the second quarter. Teton Advisors Inc. now owns 156,392 shares of the company’s stock worth $447,000 after buying an additional 1,000 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Harvard Bioscience by 399.4% in the first quarter. Goldman Sachs Group Inc. now owns 57,373 shares of the company’s stock worth $173,000 after buying an additional 45,884 shares during the period. Institutional investors and hedge funds own 66.31% of the company’s stock.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.